EZH2 and neoplasm: In conclusion, we demonstrated that the combination of an EZH2 inhibitor and a G9a inhibitor induced senescence in highly metastatic tumor cells by targeting H3K9me2 and H3K27me3 and without triggering SASP, providing a potentially promising epigenetics-based therapeutic strategy for the treatment of highly metastatic tumors.